Moderna (MRNA) Cash from Investing Activities (2018 - 2026)

Moderna (MRNA) has 9 years of Cash from Investing Activities data on file, last reported at -$76.0 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 110.41% year-over-year to -$76.0 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 55.49% decrease from a year earlier, with the FY2025 full-year figure at $1.9 billion, changed 0.15% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$76.0 million, down from -$48.0 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for MRNA reached as high as $2.0 billion in Q1 2023 and fell as low as -$3.9 billion in Q1 2022.
• Historically, Cash from Investing Activities has averaged $167.6 million across 5 years, with a median of $564.0 million in 2025.
• Across the five-year window, Cash from Investing Activities sank 2078.33% in 2022 and soared 518.64% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$1.0 billion in 2022, then surged by 48.66% to -$538.0 million in 2023, then retreated by 0.19% to -$539.0 million in 2024, then soared by 91.09% to -$48.0 million in 2025, then tumbled by 58.33% to -$76.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$76.0 million in Q1 2026, -$48.0 million in Q4 2025, and $700.0 million in Q3 2025.